Company Registration No. 07924989 (England and Wales)
MEDWAY DRIVE-THRU PHARMACY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025
PAGES FOR FILING WITH REGISTRAR
Shenward (London) Limited
Chartered Accountants & Business Advisors
1st Floor, Kirkland House
11-15 Peterborough Road
Harrow
Middlesex
HA1 2AX
MEDWAY DRIVE-THRU PHARMACY LIMITED
COMPANY INFORMATION
Directors
Mr S Majeed
Mrs N Majeed
Secretary
Mrs N Majeed
Company number
07924989
Registered office
465 Canterbury Street
Gillingham
Kent
ME7 5LJ
Accountants
Shenward (London) Limited
Chartered Accountants & Business Advisors
1st Floor, Kirkland House
11-15 Peterborough Road
Harrow
Middlesex
HA1 2AX
MEDWAY DRIVE-THRU PHARMACY LIMITED
CONTENTS
Page
Accountants' report
1
Balance sheet
2
Notes to the financial statements
3 - 7
MEDWAY DRIVE-THRU PHARMACY LIMITED
ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF MEDWAY DRIVE-THRU PHARMACY LIMITED FOR THE YEAR ENDED 31 JANUARY 2025
- 1 -

The following reproduces text of the Accountants' Report prepared in respect of the company's annual unaudited financial statements, from which the unaudited financial statements set out on pages 2 to 7 have been extracted.

"In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Medway Drive-Thru Pharmacy Limited for the year ended 31 January 2025 set out on pages 3 to 10 from the company’s accounting records and from information and explanations you have given us.

As a practising member firm of ICAS, we are subject to its ethical and other professional requirements which are detailed at https://icas.com/icas-framework-preparation-of-accounts.

This report is made solely to the Board of Directors of Medway Drive-Thru Pharmacy Limited, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Medway Drive-Thru Pharmacy Limited and state those matters that we have agreed to state to the Board of Directors of Medway Drive-Thru Pharmacy Limited, as a body, in this report in accordance with the requirements of ICAS as detailed at https://icas.com/icas-framework-preparation-of-accounts. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Medway Drive-Thru Pharmacy Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Medway Drive-Thru Pharmacy Limited. You consider that Medway Drive-Thru Pharmacy Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Medway Drive-Thru Pharmacy Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Shenward (London) Limited
Chartered Accountants & Business Advisors
1st Floor, Kirkland House
11-15 Peterborough Road
Harrow
Middlesex
HA1 2AX
"
19 January 2026
MEDWAY DRIVE-THRU PHARMACY LIMITED
BALANCE SHEET
AS AT
31 JANUARY 2025
31 January 2025
- 2 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
70,779
77,739
Tangible assets
4
25,908
19,212
96,687
96,951
Current assets
Stocks
72,157
58,640
Debtors
5
495,398
573,745
Cash at bank and in hand
133,499
137,395
701,054
769,780
Creditors: amounts falling due within one year
6
(282,677)
(378,224)
Net current assets
418,377
391,556
Total assets less current liabilities
515,064
488,507
Capital and reserves
Called up share capital
8
100
100
Profit and loss reserves
9
514,964
488,407
Total equity
515,064
488,507

The directors of the company have taken advantage under section 444 of the Companies Act 2006 to not deliver a copy of the directors' report and profit and loss account within the financial statements.true

For the financial year ended 31 January 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 of Companies Act 2006.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 15 October 2025 and are signed on its behalf by:
Mr S Majeed
Director
Company Registration No. 07924989
MEDWAY DRIVE-THRU PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025
- 3 -
1
Accounting policies
Company information

Medway Drive-Thru Pharmacy Limited is a private company limited by shares incorporated in England and Wales. The registered office is 465 Canterbury Street, Gillingham, Kent, ME7 5LJ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements have been prepared under the historical cost convention.The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on supply of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 20 years.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold buildings
Over the term of the lease
Plant and machinery
25% on reducing balance
Fixtures, fittings & equipment
25% on reducing balance
Computer equipment
Motor vehicles
25% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

MEDWAY DRIVE-THRU PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2025
1
Accounting policies
(Continued)
- 4 -
1.6
Financial instruments

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Debtors

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Creditors

Basic financial liabilities, including creditors, loans from fellow group companies are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.8
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

1.9
Leases

Rental income from operating leases is recognised on a straight line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight line basis over the lease term.

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

MEDWAY DRIVE-THRU PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2025
- 5 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
15
16
3
Intangible fixed assets
Goodwill
£
Cost
At 1 February 2024 and 31 January 2025
139,220
Amortisation and impairment
At 1 February 2024
61,481
Amortisation charged for the year
6,960
At 31 January 2025
68,441
Carrying amount
At 31 January 2025
70,779
At 31 January 2024
77,739
4
Tangible fixed assets
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 February 2024
508
64,767
65,275
Additions
-
0
12,860
12,860
At 31 January 2025
508
77,627
78,135
Depreciation and impairment
At 1 February 2024
299
45,763
46,062
Depreciation charged in the year
34
6,131
6,165
At 31 January 2025
333
51,894
52,227
Carrying amount
At 31 January 2025
175
25,733
25,908
At 31 January 2024
209
19,003
19,212
MEDWAY DRIVE-THRU PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2025
- 6 -
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
148,788
167,514
Corporation tax recoverable
73,903
72,034
Amounts owed by group undertakings
9,549
-
0
Other debtors
260,556
329,120
492,796
568,668
Deferred tax asset
2,602
5,077
495,398
573,745
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
188,726
247,662
Amounts owed to group undertakings
-
0
5,941
Corporation tax
44,669
86,652
Other taxation and social security
6,375
6,866
Other creditors
42,907
31,103
282,677
378,224
7
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the company and movements thereon:

Assets
Assets
2025
2024
Balances:
£
£
Accelerated capital allowances
2,602
5,077
2025
Movements in the year:
£
Liability/(Asset) at 1 February 2024
(5,077)
Charge to profit or loss
2,475
Liability/(Asset) at 31 January 2025
(2,602)
MEDWAY DRIVE-THRU PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2025
- 7 -
8
Called up share capital
2025
2024
Ordinary share capital
£
£
Issued and fully paid
Ordinary shares of £1 each
100
100
9
Profit and loss reserves

The only movements in reserves for the current and preceding year relate to the profit and dividends.

10
Financial commitments, guarantees and contingent liabilities
Lessee

At the reporting end date the company had total outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2025
2024
£
£
Annual rental of £18,000 for lease of shop payable over lease period
96,000
114,000
11
Parent company

The parent undertaking is Bischem Limited, a company registered in England and Wales.

T he company was under the control of Bischem Limited and ultimate control of M r S Majeed and his wife, Mrs N Majeed by virtue of 100% shareholding of Bischem Limited in both 20 25 and 2024.

Dividends paid to parent undertaking Bischem Limited during the year amounted to £99,000 (2024: £98,500).

12
Directors' transactions
Description
% Rate
Opening balance
Amounts advanced
Amounts repaid
Closing balance
£
£
£
£
Mr S Majeed -
-
299,233
2,034
(80,000)
221,267
299,233
2,034
(80,000)
221,267
2025-01-31 2024-02-01 false false false 19 January 2026 CCH Software CCH Accounts Production 2025.300 No description of principal activity Mr S Majeed Mrs N Majeed Mrs N Majeed The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.07924989 2024-02-01 2025-01-31 07924989 bus:Director1 2024-02-01 2025-01-31 07924989 bus:CompanySecretaryDirector1 2024-02-01 2025-01-31 07924989 bus:CompanySecretary1 2024-02-01 2025-01-31 07924989 bus:Director2 2024-02-01 2025-01-31 07924989 bus:RegisteredOffice 2024-02-01 2025-01-31 07924989 2025-01-31 07924989 2024-01-31 07924989 core:NetGoodwill 2025-01-31 07924989 core:NetGoodwill 2024-01-31 07924989 core:LandBuildings 2025-01-31 07924989 core:OtherPropertyPlantEquipment 2025-01-31 07924989 core:LandBuildings 2024-01-31 07924989 core:OtherPropertyPlantEquipment 2024-01-31 07924989 core:CurrentFinancialInstruments core:WithinOneYear 2025-01-31 07924989 core:CurrentFinancialInstruments core:WithinOneYear 2024-01-31 07924989 core:CurrentFinancialInstruments 2025-01-31 07924989 core:CurrentFinancialInstruments 2024-01-31 07924989 core:ShareCapital 2025-01-31 07924989 core:ShareCapital 2024-01-31 07924989 core:RetainedEarningsAccumulatedLosses 2025-01-31 07924989 core:RetainedEarningsAccumulatedLosses 2024-01-31 07924989 core:ShareCapitalOrdinaryShareClass1 2025-01-31 07924989 core:ShareCapitalOrdinaryShareClass1 2024-01-31 07924989 core:Goodwill 2024-02-01 2025-01-31 07924989 core:LandBuildings core:LeasedAssetsHeldAsLessee 2024-02-01 2025-01-31 07924989 core:PlantMachinery 2024-02-01 2025-01-31 07924989 core:FurnitureFittings 2024-02-01 2025-01-31 07924989 core:MotorVehicles 2024-02-01 2025-01-31 07924989 2023-02-01 2024-01-31 07924989 core:NetGoodwill 2024-01-31 07924989 core:NetGoodwill 2024-02-01 2025-01-31 07924989 core:LandBuildings 2024-01-31 07924989 core:OtherPropertyPlantEquipment 2024-01-31 07924989 2024-01-31 07924989 core:LandBuildings 2024-02-01 2025-01-31 07924989 core:OtherPropertyPlantEquipment 2024-02-01 2025-01-31 07924989 core:WithinOneYear 2025-01-31 07924989 core:WithinOneYear 2024-01-31 07924989 bus:OrdinaryShareClass1 2024-02-01 2025-01-31 07924989 bus:PrivateLimitedCompanyLtd 2024-02-01 2025-01-31 07924989 bus:FRS102 2024-02-01 2025-01-31 07924989 bus:AuditExemptWithAccountantsReport 2024-02-01 2025-01-31 07924989 bus:SmallCompaniesRegimeForAccounts 2024-02-01 2025-01-31 07924989 bus:FullAccounts 2024-02-01 2025-01-31 xbrli:pure xbrli:shares iso4217:GBP